newsfilter
← Latest News
GlobeNewswire·

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued neutralizing activity